SY
Sharon York Portfolio
Invests via Springhill Fund Asset Management (HK) Co. Ltd. | Managed by Sharon York
Invests via Springhill Fund Asset Management (HK) Co. Ltd.
Managed by Sharon York
Automatically Tracked
Sharon York Profile
With a distinguished career in corporate strategy and operations, Sharon York has made significant contributions across various sectors. Her expertise encompasses building high-performance teams and driving transformative growth initiatives within established organizations. Leveraging her extensive experience in market development, she has successfully navigated complex challenges to optimize business performance and increase shareholder value. As an influential leader, she plays a pivotal role in fostering innovation while guiding strategic partnerships that enhance competitive advantage. A strong advocate for sustainable practices, York's approach reflects an understanding of both macroeconomic trends and industry dynamics.
With a distinguished career in corporate strategy and operations, Sharon York has made significant contributions across various sectors. Her expertise encompasses building high-performance teams and driving transformative growth initiatives within established organizations. Leveraging her extensive experience in market development, she has successfully navigated complex challenges to optimize business performance and increase shareholder value. As an influential leader, she plays a pivotal role in fostering innovation while guiding strategic partnerships that enhance competitive advantage. A strong advocate for sustainable practices, York's approach reflects an understanding of both macroeconomic trends and industry dynamics.
Investment Philosophy & Strategy
Amidst evolving market landscapes, Sharon York pursues investment opportunities that emphasize sustainable growth and operational excellence. By focusing on strategic partnerships, she seeks to unlock synergies across various sectors while enhancing corporate value through innovation. Her ability to leverage deep industry insights positions her to identify compelling business models and assess competitive dynamics effectively. Prioritizing agility in capital deployment, the strategy revolves around fostering collaborative environments that promote creativity and efficiency within teams. This multifaceted approach aims not only for immediate results but also sets the foundation for long-term success in an increasingly interconnected global economy.
Amidst evolving market landscapes, Sharon York pursues investment opportunities that emphasize sustainable growth and operational excellence. By focusing on strategic partnerships, she seeks to unlock synergies across various sectors while enhancing corporate value through innovation. Her ability to leverage deep industry insights positions her to identify compelling business models and assess competitive dynamics effectively. Prioritizing agility in capital deployment, the strategy revolves around fostering collaborative environments that promote creativity and efficiency within teams. This multifaceted approach aims not only for immediate results but also sets the foundation for long-term success in an increasingly interconnected global economy.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
20.82%
Gain +0.02%
Monthly
1.09%
Yearly
13.91%
Drawdown
17.07%
$22.28M
Equity
Holdings
$22.28M
Investment
$20.18M
$5.75M
Profit +$4,220.52
Realized
$3.65M
Unrealized
$2.1M
Dividends
$18,247.36
Goals
Avg. 39.5% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0.02%
Profit
$4,220.52
Win %
71%
This Week
Compared To Last Week
Gain
0.02%
Profit
$4,220.52
Win %
71%
This Month
Compared to last month
Gain
-2.04%
Profit
-$492,173.78
Win %
71%
This Year
Compared to last year
Gain
-4.16%
Profit
-$1.03M
Win %
71%
SMMT Summit Therapeutics Inc.
+7.11%
+$115,605.51 
TGTX TG Therapeutics, Inc.
+3.06%
+$19,845.01 
COGT Cogent Biosciences, Inc.
+1.47%
+$14,155.62 
INSM Insmed Inc.
+1.17%
+$21,686.96 
ASND Ascendis Pharma A/S
+1.14%
+$5,345.55 
BNTX BioNTech SE
+1.12%
+$3,000 
RYTM Rhythm Pharmaceuticals Inc.
+0.82%
+$4,519.44 
REGN Regeneron Pharmaceuticals, Inc.
+0.11%
+$1,716.08 
AKRO Akero Therapeutics, Inc.
0%
$0 
SLNO Soleno Therapeutics, Inc.
0%
$0 
SWTX SpringWorks Therapeutics Inc.
0%
$0 
VRNA Verona Pharma plc
0%
$0 
LLY Eli Lilly and Company
-2.41%
-$22,807.16 
JAZZ Jazz Pharmaceuticals plc
-2.37%
-$55,275.33 
NBIX Neurocrine Biosciences Inc.
-1.81%
-$40,155.67 
TARS Tarsus Pharmaceuticals Inc.
-1.05%
-$4,670.16 
JANX Janux Therapeutics Inc.
-0.73%
-$7,850 
ARGX argenx SE American Depositary Receipt
-0.6%
-$6,211.3 
PTGX Protagonist Therapeutics Inc.
-0.01%
-$128.59 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 36 | Longs Won 15/36 41% | Profit Factor 2.15 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $547,120.88 |
| Average Win $549,278.91 | Best Trade (Mar 31) $1.66M | Sharpe Ratio -10.75 |
| Average Loss -$182,313.47 | Worst Trade (Jun 14) -$1.18M | Z-Score -1.04 (70.41%) |
| Commissions $0 | Avg. Trade Length 10m 1w 1d | Expectancy $159,597.49 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.02% | 0.53% | 8.44% |
| Consecutive Losing Trades | 122 | 110 | 98 | 86 | 73 | 61 | 49 | 37 | 24 | 12 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
